🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Geoffrey T. Gibney

Georgetown University

ORCID: 0000-0002-5401-8498

Also affiliated with Georgetown University Medical Center, MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Papers

Driven by 9 papers — median percentile 0. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437
N/A
6.5DataRank · unranked
846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

The State of Melanoma: Emergent Challenges and Opportunities

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4092
N/A
0.705DataRank · unranked
109 citations

Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso +31 more

Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004839
N/A
0DataRank · unranked
15 citations

Aparna Nallagangula, Jacob Choi, Lisa Tachiki, Matthew Blackburn, Stephen Capone +13 more

A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps9591
N/A
0DataRank · unranked
4 citations

Sandra J. Lee, Michael B. Atkins, Terence Z. Wong, Jennifer L. Guerriero, Thomas U. Marron +8 more

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

npj Precision Oncology(2023)10.1038/s41698-023-00471-z
N/A
0DataRank · unranked
24 citations

Jennifer R. Ribeiro, Jun Yin, Joanne Xiu, Matías A. Bustos, Fumito Ito +17 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis

The Oncologist(2020)10.1002/onco.13608
N/A
0DataRank · unranked
4 citations

Elisa Funck‐Brentano, Khang Nguyen, Suthee Rapisuwon, Joe‐Elie Salem, Geoffrey T. Gibney +3 more

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma

British Journal of Dermatology(2024)10.1093/bjd/ljae401
N/A
0DataRank · unranked
7 citations

Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka, Jacob Kechter +39 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256
N/A
0DataRank · unranked
98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more